We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Orion Corporation | TG:OFK | Tradegate | Ordinary Share |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.709999 | 1.92% | 37.73 | 37.66 | 37.80 | 37.30 | 37.19 | 37.19 | 20 | 22:50:06 |
ORION CORPORATION MANAGERS’ TRANSACTIONS 6 MAY 2024 at 12.00 EEST
Orion Corporation: Managers’ transactions – Ari Lehtoranta
Orion Corporation has received the following disclosure under Market Abuse Regulation (EU) No 596/2014, regarding transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons.
Orion Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Ari LehtorantaPosition: Member of the Board/Deputy memberIssuer: Orion OyjLEI: 74370029VAHCXDR7B745Notification type: INITIAL NOTIFICATIONReference number: 61582/4/4
____________________________________________Transaction date: 2024-05-03Outside a trading venueInstrument type: SHAREISIN: FI0009014377Nature of transaction: RECEIPT OF A SHARE-BASED INCENTIVE
Transaction details(1): Volume: 678 Unit price: 0 EUR
Aggregated transactions (1): Volume: 678 Volume weighted average price: 0 EUR
Orion Corporation
Liisa HurmePresident and CEO | Olli HuotariSVP, Corporate Functions |
Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandhttp://www.orion.fi/enhttp://www.twitter.com/OrionCorpIR
Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2023 amounted to EUR 1,190 million and the company had about 3,600 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.
1 Year Orion Chart |
1 Month Orion Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions